Lopez–Carmona MD, et al. – The physicians conducted this work to determine CD36 expression under different glycemic states in both healthy subjects and in atherosclerotic patients. It was showed that hyperglycemia is an important modulator of CD36 mRNA and non–glycated protein expression in vitro, increasing de novo synthesis in healthy subjects. There are progressive increases in CD36 receptors, which may be due to a post–translational stimulus in atherosclerotic patients.